A European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Dyslipidemia With or Without Other Comorbidities.
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Rimonabant (Primary)
- Indications Dyslipidaemias; Obesity
- Focus Therapeutic Use
- Acronyms ETERNAL
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 07 Jul 2009 Actual patient number (645) added as reported by ClinicalTrials.gov.
- 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.